Literature DB >> 26243785

Allergic Inflammation Is Associated With Coronary Instability and a Worse Clinical Outcome After Acute Myocardial Infarction.

Giampaolo Niccoli1, Camilla Calvieri2, Davide Flego2, Giancarla Scalone2, Asya Imaeva2, Vito Sabato2, Domenico Schiavino2, Giovanna Liuzzo2, Filippo Crea2.   

Abstract

BACKGROUND: The role of allergic inflammation in acute coronary syndromes (ACS) has not been clearly defined to date. Aim of this study was to assess eosinophil and basophil activation in ACS and the prognostic role of eosinophil cationic protein in ST-segment-elevation myocardial infarction. METHODS AND
RESULTS: In a cross-sectional study, we prospectively enrolled 51 patients undergoing percutaneous coronary intervention (60.8% patients with ACS and 39.2% with stable angina). Flow cytometry analysis assessed CD66b, CD69, and CD203c median fluorescence intensity expression. In a follow-up study, 181 patients presenting with ST-segment-elevation myocardial infarction, undergoing primary percutaneous coronary intervention, were prospectively enrolled with a follow-up of 24 months. Eosinophil activation (CD66b) was similar in patients with ACS and stable angina (6.61 [4.91-7.72] versus 6.62 [5.27-8.73], P=0.63), whereas eosinophil degranulation (CD69) and basophil activation (CD203c) were higher in ACS patients compared with stable angina patients (1.38 [1.16-1.52] versus 1.17 [1-1.31], P=0.01); 0.97 [0.89-1.11] versus 0.92 [0.87-0.95], P=0.03, respectively). Eosinophil cationic protein serum levels were significantly higher in ST-segment-elevation myocardial infarction patients with major adverse cardiac events as compared with those without (21.1 [10.37-25.65] versus 7.83 [3.37-12.8] μg/L, P=0.01) and in patients with thrombus score >3 compared with those with thrombus score ≤3 (15.0 [9.8-24.7] versus 5.2 [3.5-22.9] μg/L, P=0.006). Eosinophil cationic protein serum levels predicted major adverse cardiac events during follow-up (odds ratio =1.041, 95% confidence interval 1.012-1.071, P=0.005). C-reactive protein serum levels showed a borderline statistical significance (odds ratio =0.904, 95% confidence interval 0.806-1.014, P=0.085).
CONCLUSIONS: These findings are the first demonstration of in vivo eosinophil degranulation and basophil activation during ACS and of the prognostic role of eosinophil cationic protein in ST-segment-elevation myocardial infarction.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  acute coronary syndrome; allergic cells; inflammation

Mesh:

Substances:

Year:  2015        PMID: 26243785     DOI: 10.1161/CIRCINTERVENTIONS.115.002554

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  4 in total

1.  Temporal Changes in Pollen Concentration Predict Short-Term Clinical Outcomes in Acute Coronary Syndromes.

Authors:  Omar Al-Mukhtar; Sara Vogrin; Edwin R Lampugnani; Samer Noaman; Diem T Dinh; Angela L Brennan; Christopher Reid; Jeffrey Lefkovits; Nicholas Cox; Dion Stub; William Chan
Journal:  J Am Heart Assoc       Date:  2022-03-15       Impact factor: 6.106

Review 2.  Regulation of Type 2 Immunity in Myocardial Infarction.

Authors:  Jun-Yan Xu; Yu-Yan Xiong; Xiao-Tong Lu; Yue-Jin Yang
Journal:  Front Immunol       Date:  2019-01-29       Impact factor: 7.561

3.  Eosinophils Protect Mice From Angiotensin-II Perfusion-Induced Abdominal Aortic Aneurysm.

Authors:  Cong-Lin Liu; Xin Liu; Yuanyuan Zhang; Jing Liu; Chongzhe Yang; Songyuan Luo; Tianxiao Liu; Yunzhe Wang; Jes S Lindholt; Axel Diederichsen; Lars M Rasmussen; Marie Dahl; Galina K Sukhova; Guanyi Lu; Gilbert R Upchurch; Peter Libby; Junli Guo; Jinying Zhang; Guo-Ping Shi
Journal:  Circ Res       Date:  2020-11-06       Impact factor: 17.367

4.  High levels of tumor-associated neutrophils are associated with improved overall survival in patients with stage II colorectal cancer.

Authors:  Ryan S Berry; Meng-Jun Xiong; Alissa Greenbaum; Parisa Mortaji; Robert A Nofchissey; Fred Schultz; Cathleen Martinez; Li Luo; Katherine T Morris; Joshua A Hanson
Journal:  PLoS One       Date:  2017-12-06       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.